Caliper Life Sciences Inc. of Hopkinton, Mass., and AntiCancer Inc. of San Diego, have agreed to establish a cross-licensing relationship and to terminate all outstanding patent litigation between themselves. As part of the agreement, Caliper will acquire the right to sublicense AntiCancer’s fluorescent protein optical imaging patents to third parties. In turn, AntiCancer will acquire the right to sublicense Caliper’s optical imaging patents, in the field of fluorescent protein images, to a specified number of third parties on an annual basis throughout the life of the agreement. Each company will receive a royalty-free license from the other for internal and contract research operations.